Who owns AVALO THERAPEUTICS ORD?

Tip: Access positions for across all investors

Analyze quarterly positions in Avalo Therapeutics Ord with up to 7 years of data, all consolidated into one spreadsheet

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Top investors of Avalo Therapeutics Ord stock

Who bought or sold AVALO THERAPEUTICS ORD this quarter?

Fund or Company Name Shares Held Valued At Change in Shares As Of Actions
BVF 1.4M $17M 32% Sep 2025
 View chart
OrbiMed Advisors 1.3M $17M 40% Sep 2025
 View chart
Nantahala Capital Management 1.2M $16M 24% Sep 2025
 View chart
Point72 Asset Management 1.1M $13M 100% Sep 2025
 View chart
Affinity Asset Advisors 1.0M $13M 66% Sep 2025
 View chart
Caligan Partners 833k $11M 100% Sep 2025
 View chart
Balyasny Asset Management 817k $10M 100% Sep 2025
 View chart
Silverarc Capital Management 721k $9.2M 100% Sep 2025
 View chart
Vanguard Group 693k $8.8M 315% Sep 2025
 View chart
RA Capital Management 663k $8.4M -29% Sep 2025
 View chart
Citadel Advisors 493k $6.3M 100% Sep 2025
 View chart
TCG Crossover Management 483k $6.1M 0% Sep 2025
 View chart
Commodore Capital 483k $6.1M 0% Sep 2025
 View chart
Velan Capital Investment Management 264k $3.4M 70% Sep 2025
 View chart
Adage Capital Partners GP 259k $3.3M 100% Sep 2025
 View chart
Boothbay Fund Management 228k $2.9M 1917% Sep 2025
 View chart
Ameriprise Financial 214k $2.7M 100% Sep 2025
 View chart
Superstring Capital Management 188k $2.4M 100% Sep 2025
 View chart
Ally Bridge Group 178k $2.3M 100% Sep 2025
 View chart
Ikarian Capital 160k $2.0M 353% Sep 2025
 View chart
BlackRock 154k $2.0M -1% Sep 2025
 View chart
DLD Asset Management 152k $1.9M 100% Sep 2025
 View chart
Deep Track Capital 145k $1.8M -75% Sep 2025
 View chart
Perceptive Advisors 140k $1.8M 0% Sep 2025
 View chart
Millennium Management 137k $1.7M 100% Sep 2025
 View chart
Boxer Capital Management 125k $1.6M 100% Sep 2025
 View chart
Susquehanna International 112k $1.4M 100% Sep 2025
 View chart
Geode Capital Management 104k $1.3M -6% Sep 2025
 View chart
Exome Asset Management 100k $1.3M 100% Sep 2025
 View chart
Patient Square Capital 100k $1.3M 100% Sep 2025
 View chart
Renaissance Technologies 99k $1.3M 100% Sep 2025
 View chart
Adviser Investments 87k $1.1M -67% Sep 2025
 View chart
Cantor Fitzgerald, L. P. 85k $1.1M 100% Sep 2025
 View chart
Standard Life Aberdeen 73k $925k 100% Sep 2025
 View chart
Sio Capital Management 72k $917k 0% Sep 2025
 View chart
Marshall Wace 56k $712k 100% Sep 2025
 View chart
Two Sigma Investments 49k $626k 282% Sep 2025
 View chart
State Street Corporation 46k $578k 100% Sep 2025
 View chart
UBS Group 45k $565k -46% Sep 2025
 View chart
Walleye Trading Advisors 45k $569k 117% Sep 2025
 View chart
Landscape Capital Management 33k $424k 100% Sep 2025
 View chart
ADAR1 Capital Management 32k $412k -69% Sep 2025
 View chart
Birchview Capital 31k $394k 100% Sep 2025
 View chart
HighVista Strategies 28k $353k 100% Sep 2025
 View chart
Springbok Capital Management 25k $313k 100% Sep 2025
 View chart
Northern Trust 19k $236k -18% Sep 2025
 View chart
XTX Topco 14k $177k 100% Sep 2025
 View chart
Dimensional Fund Advisors 11k $143k 100% Sep 2025
 View chart
Barclays 9.3k $119k 100% Sep 2025
 View chart
Jpmorgan Chase & Co 1.6k $20k 42% Sep 2025
 View chart
PFS Partners 1.0k $13k 100% Sep 2025
 View chart
Simplex Trading 748.00 $9.0k 100% Sep 2025
 View chart
Group One Trading 281.00 $3.6k 28000% Sep 2025
 View chart
Tower Research Capital 26.00 $329.999800 100% Sep 2025
 View chart
SBI Securities 23.00 $292.001100 5% Sep 2025
 View chart
Morgan Stanley 10.00 $50.000000 100% Jun 2025
 View chart
Efficient Wealth Management 5.00 $0 0% Sep 2025
 View chart
Bnp Paribas Arbitrage, Snc 5.00 $64.000000 0% Sep 2025
 View chart
Advisor Group Holdings 2.00 $18.000000 0% Sep 2025
 View chart
Key FInancial 1.00 $13.000000 0% Sep 2025
 View chart
Parallel Advisors 1.00 $13.000000 0% Sep 2025
 View chart
Activest Wealth Management 1.00 $13.000000 0% Sep 2025
 View chart

Who sold out of Avalo Therapeutics Ord?

Fund or Company Name Date Sold Shares Held Valued At
Raymond James Financial Jun 2025 1.00 $5.000000